New Stock News | Yimufeng Biotech has once again submitted an application to the Hong Kong Stock Exchange. Its core product IMC002 has submitted an application for investigational new drug to the National Medical Products Administration.

According to the information disclosed by the Hong Kong Stock Exchange on August 18, the Shenzhen Yimufeng Biotechnology Co., Ltd.-B (hereinafter referred to as "Yimufeng Biotechnology") has again submitted its application to the main board of the Hong Kong Stock Exchange, with Huatai International as the sole sponsor.